By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dako today said that it has signed an agreement with Bristol-Myers Squibb to develop pharmacogenomics tests to identify patients that are more likely to respond to drugs being developed by the drug firm.

The deal builds on a similar agreement between the firms reached in 2008. Terms of the newest agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.